Table 2. Markers of endothelial function, inflammation and coagulation, and fasting lipids in patients receiving ABC, TDF and AZT.
| Marker | ABC (n=46) | TDF (n=72) | AZT (n=30) | P-value, ABC versus TDF | P-value, ABC versus AZT | P-value, TDF versus AZT |
|---|---|---|---|---|---|---|
| Mean FMD, % (SD)a | 3.9 (2.74) | 4.5 (2.74) | 6.1 (2.74) | 0.181 | <0.001 | 0.004 |
| IL-6>0.70 pg/ml, % | 28.9 | 15.5 | 27.6 | 0.121 | 0.967 | 0.299 |
| Mean hsCRP, mg/1 (SD) | 3.0 (3.5) | 2.2 (2.8) | 3.8 (4.5) | 0.197 | 0.404 | 0.086 |
| D-dimer >150 units, % | 9.3 | 13.2 | 26.7 | 0.689 | 0.064 | 0.122 |
| Mean LDL cholesterol, mg/dl (SD) | 120 (35.6) | 117 (30.9) | 108 (34.7) | 0.668 | 0.149 | 0.235 |
| Mean HDL cholesterol, mg/dl (SD) | 55 (17.3) | 53 (37.8) | 52 (14.6) | 0.762 | 0.644 | 0.815 |
| Mean triglycerides, mg/dl (3D) | 174 (191.5) | 115 (51.6) | 201 (202.0) | 0.037 | 0.430 | 0.008 |
a
Adjusted for baseline brachial artery diameter, age. and antiretroviral therapy duration. ABC, abacavir; AZT. zidovudine; FMD. flow-mediated dilation; HDL. high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; LDL, low-density lipoprotein; TDF, tenofovir.